Letter of Complaint Re: FDA Double Agent


A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.  Continue reading →

The Damaging Impact of PDUFA and Why It Should be Repealed

The re-prioritization of rapid approvals occurred at the expense of drug safety standards, Continue reading →

Eli Lilly Lies About Zyprexa_NYT Editorial Calls for CongressionalHearings

The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?

Continue reading →